© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
June 03, 2022
Lori J. Wirth, MD, discusses the treatment options now available for patients with iodine-refractory differentiated thyroid cancer.
May 12, 2022
Lori Wirth, MD, discusses her experience with NTRK-targeted therapies for patients with thyroid cancer.
December 20, 2021
Lori Wirth, MD, discusses the subanalysis of patients with thyroid cancer with NTRK fusion mutations in clinical trials for larotrectinib.
June 25, 2021
Lori Wirth, MD, discusses unmet needs and future considerations in the management of differentiated thyroid cancer.
Lori Wirth, MD, reviews key efficacy data from the post hoc analysis of the SELECT trial investigating the use of lenvatinib in patients with lung metastases.
An overview of how SELECT trial data affected clinical treatment practice for patients with differentiated thyroid cancer.